PCM
BIOS

Prelude Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Prelude Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,000
Closed -$1.6M – 1453
2023
Q2 		$1.6M Buy
+150,000
New +$1.58M 0.1% 233

Other funds holding BIOS

WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Prelude Capital Management's BIOS Position: Q3 2023 in Review

Prelude Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q3 2023, closing a stake of 150,000 shares — an estimated $1.6M sold.

Prelude Capital Management first reported a position in BIOS in Q2 2023 and held it in 1 quarter. The position peaked at $1.6M in Q2 2023. 30 funds tracked by Wall St. Rank hold BIOS as of Q3 2023.

  • Prelude Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 150,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q3 2023, an estimated $1.6M.
  • Prelude Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Prelude Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $1.6M in Q2 2023.
  • 30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.